Healthcare provider profile · identity verified

Zuhal Kadhim, MD

Family Practice · MORRILTON, AR · NPI 1497209696

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	200	103
Lisinopril	Lisinopril	166	79
Amlodipine Besylate	Amlodipine Besylate	140	74
Levothyroxine Sodium	Levothyroxine Sodium	138	60
Pantoprazole Sodium	Pantoprazole Sodium	123	50
Gabapentin	Gabapentin	117	55
Albuterol Sulfate Hfa	Albuterol Sulfate	115	48
Omeprazole	Omeprazole	113	51
Metformin Hcl	Metformin Hcl	106	53
Furosemide	Furosemide	98	39
Hydrochlorothiazide	Hydrochlorothiazide	90	41
Tamsulosin Hcl	Tamsulosin Hcl	87	37
Losartan Potassium	Losartan Potassium	82	34
Potassium Chloride	Potassium Chloride	68	29
Trazodone Hcl	Trazodone Hcl	67	33
Glipizide	Glipizide	66	32
Metoprolol Tartrate	Metoprolol Tartrate	64	31
Carvedilol	Carvedilol	59	24
Jardiance	Empagliflozin	59	21
Ozempic	Semaglutide	59	22
Duloxetine Hcl	Duloxetine Hcl	56	22
Allopurinol	Allopurinol	51	22
Simvastatin	Simvastatin	50	27
Meloxicam	Meloxicam	49	21
Pravastatin Sodium	Pravastatin Sodium	49	22
Metoprolol Succinate	Metoprolol Succinate	45	18
Sertraline Hcl	Sertraline Hcl	44	16
Mounjaro	Tirzepatide	41	18
Clopidogrel	Clopidogrel Bisulfate	38	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	38	19
Citalopram Hbr	Citalopram Hydrobromide	36	17
Eliquis	Apixaban	36	13
Fluoxetine Hcl	Fluoxetine Hcl	36	17
Rosuvastatin Calcium	Rosuvastatin Calcium	36	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	35	21
Alendronate Sodium	Alendronate Sodium	34	12
Metformin Hcl Er	Metformin Hcl	33	17
Quetiapine Fumarate	Quetiapine Fumarate	33	12
Glipizide Er	Glipizide	32	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	32	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	17
Buspirone Hcl	Buspirone Hcl	30	19
Diclofenac Sodium	Diclofenac Sodium	30	suppressed
Topiramate	Topiramate	30	11
Trulicity	Dulaglutide	30	suppressed
Montelukast Sodium	Montelukast Sodium	29	16
Tizanidine Hcl	Tizanidine Hcl	28	13
Atenolol	Atenolol	26	12
Escitalopram Oxalate	Escitalopram Oxalate	25	14
Famotidine	Famotidine	23	suppressed
Mirtazapine	Mirtazapine	23	12
Clonazepam	Clonazepam	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	11
Tramadol Hcl	Tramadol Hcl	22	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Bumetanide	Bumetanide	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	12
Levetiracetam	Levetiracetam	19	suppressed
Bupropion Xl	Bupropion Hcl	18	suppressed
Prednisone	Prednisone	18	17
Azithromycin	Azithromycin	17	16
Clonidine Hcl	Clonidine Hcl	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	11
Promethazine Hcl	Promethazine Hcl	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Nitroglycerin	Nitroglycerin	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	13	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Ezetimibe	Ezetimibe	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error